Clostridium butyricum CBM588: Butyrate-Maker Probiotic Evidence

Most probiotics on the shelf are Lactobacillus and Bifidobacterium. Clostridium butyricum CBM588 is something different: a spore-forming, butyrate-producing bacterium that has been used as a regulated medicinal and food probiotic in Japan for decades (where it's better known as C. butyricum MIYAIRI 588, sold as Miyarisan), and which carries EU food and supplement approval. That long regulatory pedigree, plus a genuinely interesting recent run of cancer-immunotherapy trials, has pushed CBM588 into the "metabolic health" conversation. This page does the honest sorting: where the evidence is real and strong, where it's a promising signal, and where the metabolic claims are an extrapolation that runs ahead of the human data.

The one-line version: CBM588's best-established uses are gastrointestinal — preventing antibiotic-associated diarrhea and supporting the gut after eradication therapy — and its most striking recent data are as an oncology adjunct, not a metabolic supplement. The insulin-sensitivity and anti-inflammatory story is mechanistically reasonable and has a few human and animal hints, but it is markedly thinner than the GI and cancer literature. Don't buy it as a blood-sugar pill.

What CBM588 actually is

CBM588 is a strain of Clostridium butyricum, an anaerobic, spore-forming bacterium whose defining trick is that it ferments undigested carbohydrate into butyrate — the short-chain fatty acid that fuels the cells lining your colon and underpins much of the "gut health" story. In that sense it's a live version of the butyrate goal: instead of swallowing a butyrate salt and hoping it survives to the colon (the delivery problem we unpack in butyrate supplements and foods), you deliver a spore that germinates in the gut and produces butyrate on-site. Like the Bacillus strains we cover in spore-based and soil-based probiotics, CBM588's spore form gives it real survival through the acidic upper gut — a meaningful delivery advantage, though, as always, survival is a necessary condition for benefit, not proof of one.

The strain has been characterized as a probiotic with effects on gastrointestinal infections and the gut microbiota, and its butyrogenic, anti-inflammatory mechanisms are reasonably well described in reviews ¹. But "well-described mechanism" and "proven human outcome" are different tiers, and CBM588's evidence is spread unevenly across them.

The established uses: antibiotic-associated diarrhea and GI support

This is where CBM588 has its firmest footing, and it's worth leading with because it's also where the regulatory history comes from.

In a randomized study of children receiving antibiotics, C. butyricum MIYAIRI given concomitantly reduced the incidence of antibiotic-associated diarrhea compared with controls — a clean, clinically relevant outcome and one of the cleaner results in the whole literature ². The same strain has been studied as an add-on to Helicobacter pylori eradication therapy: a controlled study found that concomitant C. butyricum improved outcomes in relation to the gut flora disruption that eradication antibiotics cause ³, and an earlier study documented its favorable effect on fecal flora during eradication therapy ⁴. A focused review of C. butyricum in gastrointestinal infections summarizes this body of work and the plausible barrier-and-butyrate mechanisms behind it ¹.

Read honestly, the GI evidence is the category CBM588 has actually earned. It's not enormous and much of it is older and Japanese, but it consists of real clinical endpoints (diarrhea incidence, flora protection) in the setting where butyrate-producing support makes the most mechanistic sense — protecting a microbiome being hammered by antibiotics. If you're rebuilding gut flora, that's the same logic we walk through in rebuilding your gut after antibiotics.

The headline data: CBM588 as an oncology adjunct

The reason CBM588 has a moment right now isn't metabolic — it's oncology. In a randomized trial in metastatic renal cell carcinoma, adding CBM588 to the immunotherapy combination nivolumab plus ipilimumab was associated with improved progression-free survival and response versus the checkpoint inhibitors alone, with the live bacterial supplement appearing to favorably shift the gut microbiome ⁵. A second randomized trial in the same cancer paired CBM588 with cabozantinib plus nivolumab and again reported microbiome modulation and an efficacy signal ⁶. The proposed mechanism ties directly to the strain's identity: butyrate and other short-chain fatty acids influence the anti-tumor immune response to checkpoint inhibitors, which is the rationale reviewed for SCFA-producing probiotics in immunotherapy ⁷.

These are small, early, single-center randomized trials — provocative and genuinely important, but not practice-defining, and emphatically not a green light to self-prescribe a probiotic alongside cancer treatment. We flag them here because they are, by a wide margin, the strongest outcome signal CBM588 has, and because they show the bacterium can measurably reshape the microbiome in people. That matters for interpreting the metabolic claims — but it is not itself metabolic evidence.

The metabolic story: thinner than the marketing implies

Here is the section the supplement copy skips. The leap from "butyrate-producing probiotic with real GI and oncology data" to "insulin-sensitizing metabolic supplement" is mostly mechanism and animal work, with only oblique human support.

The mechanism is reasonable. Butyrate stimulates the gut's own GLP-1 and PYY release, reinforces the gut barrier, and exerts anti-inflammatory effects via HDAC inhibition — the same SCFA→metabolism machinery that connects any butyrate-producer to insulin sensitivity. We map that pathway in our gut–metabolism connection pillar and in the microbiome and insulin resistance. A live butyrate factory in the colon is, in principle, a sensible way to engage it.

The animal data are encouraging but preclinical. C. butyricum MIYAIRI 588 improved high-fat-diet-induced non-alcoholic fatty liver disease in rats, a metabolically relevant result that fits the mechanism ⁸. That's a real finding — and it's a rodent NAFLD model, not a human metabolic trial.

The human metabolic data are indirect. The cleanest human glycemic signals for butyrate-producing probiotics come not from CBM588 alone but from a defined multi-strain formula (which includes C. butyricum alongside other species and a prebiotic). A randomized, double-blind trial of that combination reported improvements in postprandial glucose control in people with type 2 diabetes ⁹, and a companion analysis found the intervention raised circulating butyrate during treatment ¹⁰. This is the best human metabolic evidence in the vicinity — but you cannot attribute it to CBM588 specifically, because the strain was bundled with others and a fiber. It tells you the category of butyrate-raising probiotics can nudge glucose; it does not establish CBM588 as a stand-alone insulin-sensitizer.

So the honest tiering: CBM588's metabolic case rests on a sound mechanism, a rat NAFLD study, and human glucose data from a multi-strain formula it happens to belong to. That's a promising hypothesis, not a proven metabolic treatment — and it sits well behind the GI and oncology evidence. For where butyrate-raising probiotics land overall on blood sugar, see our best probiotics for blood sugar review.

Safety: the standard live-probiotic caveat, with a real-world footnote

CBM588 has a long human-use record in Japan and a generally reassuring tolerability profile in the studies above, with GI complaints the usual minor issue. But it is a live organism, and the standard probiotic safety caveat applies with specific, documented force here: live probiotics carry a rare risk of bacteremia (bloodstream infection) in immunocompromised, critically ill, or post-surgical patients. This is not theoretical for C. butyricum — there are published, genomically confirmed case reports of probiotic-related C. butyricum bacteremia, including after COVID-19 and after major abdominal surgery, traced to the probiotic strain itself ¹¹¹²¹³.

The practical translation: for healthy adults, CBM588 has a long, reassuring track record. But anyone who is immunocompromised, seriously ill, hospitalized, has a central venous catheter, or is undergoing major surgery should not start a live probiotic without clearing it with their clinician — and the people most likely to be drawn to the oncology data are often precisely the people for whom that caution matters most.

The bottom line

Clostridium butyricum CBM588 is one of the more genuinely interesting probiotics on the market: a butyrate-producing, spore-forming strain with decades of regulated use, real clinical data for antibiotic-associated diarrhea and gut support, and a striking — if early — run of cancer-immunotherapy trials. What it is not, on current evidence, is a proven metabolic or blood-sugar supplement. The insulin-sensitivity and anti-inflammatory claims are mechanistically reasonable and have a rat NAFLD study plus human glucose data from a multi-strain formula behind them, but no stand-alone human trial establishes CBM588 as a metabolic treatment. Treat the metabolic angle as a plausible extrapolation, respect the rare-but-real bacteremia risk in vulnerable patients, and judge it for what the evidence actually supports. To compare gut-metabolic products through the same evidence-tiered lens, see our best metabolic probiotic hub and our best gut-health supplements review.